Methotrexat Accord

Methotrexate, the active ingredient in Methotrexat Accord, is an antimetabolite (folate antagonist) presented as a sterile solution for intra‑arterial, intramuscular, intravenous use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, osteosarcoma, and gestational trophoblastic disease in appropriate patient populations.

GNH USA supplies Methotrexat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is employed in autoimmune and oncologic conditions that involve rapid cell proliferation or immune‑mediated inflammation.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant lymphoblast replication. - Osteosarcoma: inhibits tumor growth and metastasis. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe, depending on dose, route, and patient factors.

Common Side Effects: - Nausea and vomiting. - Mucositis or mouth sores. - Fatigue and lethargy. - Transient liver enzyme elevation. - Mild bone marrow suppression (e.g., reduced white blood cells). - Alopecia (hair thinning or loss).

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Persistent or severe myelosuppression leading to infection. - Pulmonary toxicity, including interstitial pneumonitis. - Renal impairment or failure. - Life‑threatening hypersensitivity reactions. - Development of secondary malignancies.

Methotrexate requires careful monitoring and specific safety measures before and during therapy.

- Baseline assessment: obtain liver function tests, renal function, and complete blood count prior to initiation. - Monitoring: conduct regular laboratory evaluations to detect hepatotoxicity or myelosuppression. - Pregnancy avoidance: contraindicated in pregnancy (Category X); ensure effective contraception for both sexes. - Drug interactions: avoid concomitant use with nephrotoxic or hepatotoxic agents without supervision. - Patient education: advise on signs of infection, bleeding, or severe mucosal ulceration. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Proton pump inhibitors: may elevate methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: potentiate myelosuppression.

Moderate Interactions (Monitor Closely): - Penicillins and other antibiotics: may affect renal clearance. - Phenytoin and other enzyme inducers: reduce methotrexate effectiveness. - Vitamin supplements containing folic acid: can diminish therapeutic activity, requiring dose adjustment.